

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 29, 2014

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 23, 2013 meeting (pages 3-9; Tab 1)
- IV. Secretary's report (page 11; Tab 2)
- V. New Business
  - A. Educational newsletter for Acute Pain Treatment Options (pages 13-14; Tab 3)
  - B. Protocols review (pages 15-19; Tab 4)
    1. Buprenorphine/naloxone and buprenorphine (Suboxone®/Subutex®)
    2. Tadalafil (Cialis®)
- VI. Informational Highlights/Reports
  1. Molina Prior Authorization Report (pages 21-23; Tab 5)
  2. NJ HMO Reports 3<sup>rd</sup> Quarter 2013(pages 24-27; Tab 5)
  3. Summary of DURB Action Items (page 29; Tab 6)
  4. DHS and DHSS Programs Top Drugs Report (pages 31-44; Tab 7)
  5. Medication information: (Tab 8)
    - (a) New Cholesterol Treatment Guidelines (NEJM) (pages 45-48; Tab 8)
    - (b) JNC-8 Guidelines (pages 49-62; Tab 8)
    - (c) FDA to Recommend Reclassification of Hydrocodone combination Products (Page 63; Tab 8)
    - (d) Bill on Prescription Monitoring Program (pages 65-76; Tab 8)